He notes that the annuity stream from milestone and royalty payments of Wafermine is on track, with out-licensing partner Seelos Therapeutics planning phase 2 trials for (CRPS) in 2QFY2023 ending June 2023.
PhillipCapital’s head of research Paul Chew has maintained his “buy” call on iX Biopharma, but has lowered his target price by almost 30% downwards, from 35.5 cents to 25 cents.
Writing in a Sept 30 report, Chew explains that prospects for the company are highly dependent on development milestone payments and sales royalties from the drug Wafermine, which is used for complex regional pain syndrome (CRPS).
